Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EDSA OTCMKTS:LTUS NASDAQ:THAR NYSEAMERICAN:TOVX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDSAEdesa Biotech$2.36-1.3%$2.22$1.55▼$5.00$16.33M0.2722,033 shs665 shsLTUSLotus Pharmaceuticals$0.01-6.6%$0.01$0.00▼$0.01$22.48M-2.545,075 shs645 shsTHARTharimmune$5.95-1.7%$2.17$0.95▼$9.08$33.86M1.1730.49 million shs5.47 million shsTOVXTheriva Biologics$0.41-0.9%$0.44$0.37▼$7.15$3.94M0.771.06 million shs143,297 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDSAEdesa Biotech0.00%-1.67%+3.74%+18.00%-46.85%LTUSLotus Pharmaceuticals0.00%+1.19%-13.27%+37.10%+193.10%THARTharimmune0.00%+26.06%+376.38%+299.33%+104.47%TOVXTheriva Biologics0.00%-4.32%-8.11%-10.83%-88.61%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEDSAEdesa Biotech2.1632 of 5 stars2.05.00.00.03.31.70.6LTUSLotus PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ATHARTharimmune3.3904 of 5 stars3.85.00.00.02.92.50.0TOVXTheriva Biologics1.754 of 5 stars3.05.00.00.00.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEDSAEdesa Biotech 4.00Strong Buy$5.00111.86% UpsideLTUSLotus Pharmaceuticals 0.00N/AN/AN/ATHARTharimmune 3.50Strong Buy$17.00185.71% UpsideTOVXTheriva Biologics 2.00Hold$6.001,363.41% UpsideCurrent Analyst Ratings BreakdownLatest TOVX, LTUS, THAR, and EDSA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025EDSAEdesa BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$5.00(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEDSAEdesa BiotechN/AN/AN/AN/A$0.70 per shareN/ALTUSLotus PharmaceuticalsN/AN/AN/AN/AN/AN/ATHARTharimmuneN/AN/AN/AN/A$0.06 per shareN/ATOVXTheriva BiologicsN/AN/AN/AN/A$1.11 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEDSAEdesa Biotech-$6.17M-$1.32N/AN/AN/AN/A-162.95%-60.33%N/ALTUSLotus Pharmaceuticals$110KN/A0.00∞N/AN/AN/AN/AN/ATHARTharimmune-$12.20M-$6.10N/A∞N/AN/A-1,239.20%-365.06%N/ATOVXTheriva Biologics-$25.65M-$33.06N/A∞N/AN/A-169.31%-82.41%N/ALatest TOVX, LTUS, THAR, and EDSA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025THARTharimmune-$0.58-$0.64-$0.06-$0.64N/AN/A8/8/2025Q3 2025EDSAEdesa Biotech-$0.26-$0.25+$0.01-$0.25N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEDSAEdesa BiotechN/AN/AN/AN/AN/ALTUSLotus PharmaceuticalsN/AN/AN/AN/AN/ATHARTharimmuneN/AN/AN/AN/AN/ATOVXTheriva BiologicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEDSAEdesa BiotechN/A18.9618.96LTUSLotus PharmaceuticalsN/AN/AN/ATHARTharimmuneN/A1.171.17TOVXTheriva Biologics0.151.191.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEDSAEdesa Biotech5.50%LTUSLotus PharmaceuticalsN/ATHARTharimmune1.16%TOVXTheriva Biologics6.17%Insider OwnershipCompanyInsider OwnershipEDSAEdesa Biotech22.60%LTUSLotus PharmaceuticalsN/ATHARTharimmune10.01%TOVXTheriva Biologics1.46%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEDSAEdesa Biotech207.04 million5.45 millionNot OptionableLTUSLotus Pharmaceuticals2302.64 billionN/ANot OptionableTHARTharimmune25.69 million5.12 millionNot OptionableTOVXTheriva Biologics209.60 million9.46 millionNot OptionableTOVX, LTUS, THAR, and EDSA HeadlinesRecent News About These CompaniesTheriva Biologics, Inc. (NYSEAMERICAN:TOVX) Short Interest UpdateAugust 22, 2025 | americanbankingnews.comTheriva Biologics, Inc.: Theriva Biologics Reports Second Quarter 2025 Operational Highlights and Financial ResultsAugust 12, 2025 | finanznachrichten.deTheriva Biologics Faces Financial Risks Amid Shifting Trade Policies and TariffsAugust 12, 2025 | msn.comTheriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial ResultsAugust 11, 2025 | globenewswire.comTheriva Biologics Sets 2025 Shareholder Meeting DateJune 25, 2025 | tipranks.comTheriva Biologics, Inc.: Theriva Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at ASCO 2025 and Investigator Meeting to Review ...May 29, 2025 | finanznachrichten.deTheriva™ Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at ASCO 2025 and Investigator Meeting to Review Topline Data from the ...May 29, 2025 | morningstar.comMTheriva Biologics, Inc.: Theriva Biologics Reports First Quarter 2025 Operational Highlights and Financial ResultsMay 14, 2025 | finanznachrichten.deTheriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial ResultsMay 14, 2025 | globenewswire.comTheriva Biologics, Inc.: Theriva Biologics Announces Closing of $7.5 Million Public OfferingMay 9, 2025 | finanznachrichten.deTheriva Biologics Announces Pricing of Public Offering for $7.5 Million to Support Cancer Therapeutics DevelopmentMay 9, 2025 | nasdaq.comTheriva Biologics Announces Closing of $7.5 Million Public OfferingMay 8, 2025 | globenewswire.comTheriva Biologics, Inc.: Theriva Biologics Announces Pricing of $7.5 Million Public OfferingMay 7, 2025 | finanznachrichten.deTheriva’s oncolytic virus succeeds in pancreatic cancer study, but stock fallsMay 7, 2025 | endpts.comETheriva Biologics Announces Pricing of $7.5 Million Public OfferingMay 7, 2025 | globenewswire.comTheriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant RecipientsApril 10, 2025 | globenewswire.comTheriva Biologics Completes Enrollment For VIRAGE Trial, Topline Data Expected In Q2 2025April 2, 2025 | nasdaq.comTheriva Biologics says IDMC considers VCN-01 to be well toleratedApril 2, 2025 | markets.businessinsider.comTheriva Biologics to Present at the CAGLA NeauxCancer 2025 Conference in New OrleansMarch 21, 2025 | nasdaq.comTheriva™ Biologics to Present at the 2025 NeauxCancer ConferenceMarch 19, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTOVX, LTUS, THAR, and EDSA Company DescriptionsEdesa Biotech NASDAQ:EDSA$2.36 -0.03 (-1.26%) Closing price 08/29/2025 03:58 PM EasternExtended Trading$2.31 -0.05 (-2.33%) As of 08/29/2025 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.Lotus Pharmaceuticals OTCMKTS:LTUS$0.0085 0.00 (-6.59%) As of 08/29/2025 01:58 PM EasternLotus Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development, manufacture, and sale of pharmaceuticals in the People's Republic of China. The company is based in Nashville, Tennessee.Tharimmune NASDAQ:THAR$5.95 -0.10 (-1.65%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$5.85 -0.10 (-1.66%) As of 08/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.Theriva Biologics NYSEAMERICAN:TOVX$0.41 0.00 (-0.92%) Closing price 08/29/2025 04:10 PM EasternExtended Trading$0.41 0.00 (-0.49%) As of 08/29/2025 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors. It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. It has collaboration agreements with The University of Texas at Austin, Catalan Institute of Oncology, Fundació Privada Institut d'Investigacio Biomedica de Bellvitge, Saint Joan De Déu, and Massachusetts General Hospital, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
